Search
Caroverine
go.drugbank.com/drugs/DB13835InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSodium bisulfite
go.drugbank.com/drugs/DB14015ApprovedWithdrawnSodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.
Synonyms: Bisulfite de sodiumMixtures: NEOFLEKS IZOPLEN-P % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 1000 ML SETLI, NEOFLEKS IZOPLEN-P % 5 DEKSTROZLU DENGELI ELEKTROLIT IÇEREN INFÜZYON IÇIN ÇÖZELTI 250 ML SETLIFurafylline
go.drugbank.com/drugs/DB14029ExperimentalFurafylline is a derivative of methylxanthine derivative. It was developed on the context of asthma as a long-acting alternative for theophylline.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsDexverapamil
go.drugbank.com/drugs/DB14063ExperimentalCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEmopamil
go.drugbank.com/drugs/DB14064ExperimentalPrevents renal injury after warm & cold ischemia.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates8-chlorotheophylline
go.drugbank.com/drugs/DB14132Experimental8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar to caffeine. Its main use is in combination with Diphenhydramine as the antiemetic drug Dimenhydrinate. The stimulant properties ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesFluprednisolone acetate
go.drugbank.com/drugs/DB14637ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMelengestrol acetate
go.drugbank.com/drugs/DB14659ExperimentalA 6-methyl progesterone acetate with reported glucocorticoid activity and effect on estrus.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersTemsavir
go.drugbank.com/drugs/DB14675InvestigationalCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPegzilarginase
go.drugbank.com/drugs/DB14780ApprovedPegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D). … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.